The use of epidermal growth factor receptor (EGFR) inhibitors in several epithelial tumors
has increased considerably in recent years. Currently, they are approved in non-small cell …

The growing investigation and use of epidermal growth factor receptor (EGFR) inhibitors in
anticancer therapy has been motivated by their specificity for EGFR, which improves their …

Biologic agents targeting the epidermal growth factor receptor (EGFR) have emerged as a
robust treatment option for various solid tumors. Despite lower systemic side effects than …

The last few years, new therapies targeting the epidermal growth factor receptor (EGFR)
have shown their efficacy in the treatment of several types of cancer. Monoclonal antibodies …

The human epidermal growth factor receptor (HER1/EGFR/ErbB1) signaling is aberrant and
overexpressed in many solid malignancies making it an appealing target for biologic agents …

Epidermal growth factor receptor inhibitors (EGFRIs) have demonstrated improved overall
survival in patients with non-small cell lung cancer, pancreatic cancer, and colorectal …

The epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase that is frequently
mutated or overexpressed in a large number of tumors such as carcinomas or glioblastoma …

Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic
dermatologic side effects. Cetuximab, erlotinib, and gefitinib have been approved for …

Inhibition of the epidermal growth factor receptor (EGFR) is an established treatment that
extends patient survival across a variety of tumor types. EGFR inhibitors fall into two main …

Tyrosine kinase inhibitors (TKIs) that target epidermal growth factor receptor (EGFR) have
dramatically improved progression-free survival in non-small-cell lung cancer (NSCLC) …